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ABSTRACT
Background: Gene–environment interaction is an important aspect in the development of coronary artery disease 
(CAD). The mutation (677C-T) of methylenetetrahydrofolate reductase (MTHFR) gene results in a decrease 
of the enzyme activity that leads to mild hyperhomocysteinemia. Elevated plasma level of homocysteine has 
been recognized as an independent risk factor for cardiovascular disease. A case–control study was designed to 
assess whether the prevalence of some MTHFR gene polymorphisms have any role in the development of CAD.
Materials and Methods: The study included unrelated 217 cases with CAD and 255 healthy controls. DNA 
was extracted from peripheral blood. MTHFR genotypes were identiﬁ  ed by seeing the presence or absence of 
677CT mutation obtained by PCR followed by Hinf1 restriction digestion. Multiple logistic regression analysis 
was carried out to ﬁ  nd association between studied genotypes and lifestyle as well as biochemical risk factors.
Results: The T allele was found to be associated with the disease. Signiﬁ  cant associations were found with 
smoking, hypertension, diabetes, and family history of CAD. Conclusion: The results indicate that MTHFR 
677C-T polymorphism has signiﬁ  cant association with CADs in the population of eastern India.
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INTRODUCTION
It has been predicted that cardiovascular diseases will 
increase rapidly in India, and this country will be the host 
to more than half the cases of heart disease in the world 
within the next 15 years.[1] Global Burden of Disease 
Study estimated that India faces the greatest burden due 
to coronary artery disease (CAD).[2] Ischemic heart disease 
(IHD), myocardial ischemia (MI), is a disease resulting 
reduced blood supply to the heart muscle, usually due to 
CAD (atherosclerosis of the coronary arteries). According 
to the Framingham Heart Study[3] in USA, played vital 
role in defining the risk factors for coronary heart 
disease (CHD) incidence in general population. CAD is 
a multifactorial disorder that is thought to result from an 
interaction between genetic background and environmental 
factors. Major risk factors are lifestyle habits, smoking, 
alcohol intake, hypercholesterolemia (a condition with 
high levels of bad cholesterol or low density lipoprotein), 
diabetes, hypertension (a condition with a blood pressure 
greater than or equal to 140 mmHg systolic pressure or 
greater than or equal to 90 mmHg diastolic pressure in 
an adult), obesity, positive family history, small dense low 
density lipoprotein (LDL) particles, lipoprotein A, serum 
homocysteine, and abnormalities in several coagulation 
factors. Interactions between genetic and environmental 
factors inﬂ  uence progression of pathological processes, 
clinical characteristics of disease, and susceptibility to Dhar, et al.: Genetic predisposition of MTHFR gene polymorphisms
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therapeutic treatment.[4] Genetic factors help in explaining 
the molecular basis of the disorder and in designing 
prevention and treatment of the disease.
Homocysteine is an emerging new risk factor for cardiovascular 
disease. Systematic reviews of observational (cohort and 
case–control) studies have consistently shown a strong, 
positive, and dose-related association between the serum 
concentration of total homocysteine (tHcy) and the risk of 
stroke, which is independent of other vascular factors[5,6] The 
term homocyst(e)ine is used to deﬁ  ne the combined pool 
of homocysteine, homocystine, mixed disulﬁ  des involving 
homocysteine, and homocysteine thiolactone, and protein-
bound homocysteine.[7-9] Protein-bound homocysteine 
accounts for 70–80% of the total pool. Homocysteine is 
a nonprotein forming, sulfhydryl-containing amino acid, 
which results from methionine metabolism. Methionine, an 
essential amino acid (present in meat, milk, eggs, legumes, 
etc.), is activated to form S-adenosylmethionine (SAM), the 
universal methyl group donor. Homocysteine acts at the 
intersection of two metabolic pathways, the transsulfuration 
pathway and the remethylation cycle. Homocysteine is 
either transsulfurated to cystathionine or remethylated to 
methionine depending on methionine supplied by diet.[10] 
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme 
which plays an important role in homocysteine metabolism by 
catalyzing the reduction of 5,10-methylenetetrahydrofolate 
to 5-methyltetrahydrofolate. 5-Methyltetrahydrofolate is 
the major circulatory form of folate and carbon donor 
for remethylation of homocysteine to methionine.[4] The 
human MTHFR gene is located at chromosome 1p36.3 
and consists of 11 exons with a length of 1980 bp.[11] The 
C to T missense mutation in exon 4 at codon 677 of the 
MTHFR gene (677C→T), which causes an alanine (A) to 
valine (V) substitution in the MTHFR protein, produces a 
thermolabile form of the enzyme, reduces enzyme activity, 
and results in increased plasma homocysteine.[12] Elevated 
plasma level of homocysteine has been recognized as an 
independent risk factor for cardiovascular disease,[13] but the 
strength of the relationship and the interaction of plasma 
homocysteine with other risk factors are unclear.[14,15] The 
main mechanisms of HCY atherogenic action are thought 
to be LDL oxidation, inhibition of vascular endothelium 
growth combined with stimulation of smooth muscular 
cells proliferation, and interference with the coagulation 
and ﬁ  brinolytic systems.[14,16] A point mutation in the gene 
encoding MTHFR has been associated with elevations in 
homocysteine levels in homozygous carriers (TT genotype) 
and is considered as an independent risk factor for vascular 
diseases.[17] Homozygosity for this 677T variant was shown 
to be associated with increased plasma Hcy levels, particularly 
when folate status is low[18,19] and it has been described as a 
risk factor for CAD, although this association is not clearly 
established at present.[20]
To the best of our knowledge, this is the first study 
to report on probable association of certain MTHFR 
polymorphisms as predisposing factors in the development 
of the CAD and their interactions with relevant biochemical 
and lifestyle factors in the population of eastern India.
MATERIALS AND METHODS
Choice of study subjects
Choice of  individuals
A total of 217 clinically diagnosed cases with CADs were 
chosen from the outdoor of Cardiology Department of 
Ramakrishna Mission Seva Pratishthan. A total of 255 
age- and sex-matched healthy controls were taken for 
the study with no heart-related complains. All subjects 
underwent coronary angiography to conﬁ  rm the presence 
of the disease. 
Collection of  personal and family history
Detailed history regarding their clinical, lifestyle, and 
socioeconomic conditions were collected. Detailed status 
of the relevant biochemical parameters was noted from 
their recent investigations.
Maintenance of  ethical background
Informed written consents were obtained from all subjects. 
All the study subjects were Bengali, Indian and belonged 
to the same ethnic group. The research protocol was 
approved by the ethical and research advisory committee 
of the institution.
MTHFR polymorphism study
Collection of  blood
Blood samples, 2–3 mL, were collected from each 
individual in an EDTA vial.
Isolation of  DNA
Genomic DNA was extracted from peripheral blood 
leukocytes by salting out method.[21]
PCR–RFLP method to detect the genotypes
MTHFR genotype study was carried out to identify the 
presence of 677CT mutation as described by Frosst et 
al.[12] The PCR product (198 bp) was digested with Hinf1 
restriction enzyme.
Agarose gel electrophoresis to detect the genotypes
The mutation 677C-T creates a Hinf1 recognition sequence, 
and the product was digested into 175 bp and 23 bp Dhar, et al.: Genetic predisposition of MTHFR gene polymorphisms
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Table 3: Distribution of MTHFR genotypes and allele 
frequencies of the study groups
Genotype 
frequencies
Allele frequencies
CC CT TT C allele T allele
Case (n) 0.512 0.21 0.26 0.63 0.40 
H = 1.01*
Control (n) 0.73 0.14 0.12 0.8 0.2 
H = 1*
*Chi-square tests (with df = 2) were performed to check whether the population 
were in Hardy–Weinberg equilibrium.
fragments. The products of restriction digestion were 
separated on a 3% agarose gel and visualized by ethidium 
bromide staining. Genotypes of all individuals were noted as 
CC: 198 bp; CT: 198 bp, 175 bp, 23 bp; and TT: 175 bp, 23 bp.
All the results were checked twice in double blind.
Statistical analysis
To test for significance of observed interactions, 
likelihood ratio tests were conducted using a Chi-square 
test. The odd-ratios (OR) for different association models 
were calculated with 95% conﬁ  dence interval (CI) and 
simultaneously P values were calculated. A value of P 
< 0.05 was considered as statistically signiﬁ  cant. Extent 
of other risk factors was compared between cases 
and controls and across genotype levels. The stepwise 
logistic regression analysis was performed with the SPSS 
Statistical Package (version 14) for the determination of 
the independent risk factors for CAD. Multivariate logistic 
regression was used to obtain the OR estimate and 95% 
CI for the main effects of smoking and main enzyme 
genotype. An adjustment was made for the potential 
confounding effects of age, sex, alcohol consumption, 
tobacco consumption, family history, coexistence of 
hypertension, diabetes, etc. Dummy variables were 
created each representing the combination of category 
and genotype. In addition, interaction terms including 
duration or amount of exposure were evaluated for 
statistical signiﬁ  cance. 
RESULTS
Different lifestyle as well as demographic characteristics 
of the subjects are shown in Table 1. Out of all cases, 
44.7% were both cigarette and bidi (a dry-rolled temburni 
leaf containing ﬁ  ne tobacco dust) smokers and 78.06% 
of the controls were addicted to other tobacco habits 
(catechu, zarda, etc). Though the frequency of alcohol 
intake was higher among the cases than the control, it did 
not have any statistical impact on the disease. Observed 
data strongly correlate the incidence of the disease with 
family history. Statistical signiﬁ  cance found in the case 
of diabetes and hypertension, which elevates the risk of 
the disease.
Biochemical parameters such as HDL, LDL, serum 
cholesterol, and serum triglyceride were shown in Table 2. 
These parameters were signiﬁ  cantly associated with CAD. 
Increased level of total cholesterol and LDL cholesterol 
were obtained in the cases as expected. Serum LDL 
cholesterol and triglyceride concentration were elevated 
in CAD patients in comparison with control subjects. The 
Table 1: Characteristics of the study subjects
Cases 
(N = 217)
P* Controls 
(N = 255)
Age (years)
     Range 29–81 – 18-66
     Average 42.60 40.53
Gender (n,%)
     Male 119 (54.8) <0.05 140 (54.90)
     Female 98 (45.16) 115 (45.09)
Lifestyle habits (n,%)
     Smoking 97 (44.7) <0.01 49 (19.21)
     Other tobacco habit 129 (59.44) <0.01 199 (78.03)
     Alcohol intake 89 (41.01) NS 23 (9.01)
Family history (n, %) 72 (33.33) <0.001 36 (14.11)
Diabetes (n, %)** 82 (37.78) <0.001 32 (12.54)
Hypertension (n, %) 183 (84.33) <0.01 23 (9.01)***
*P = Calculated as Chi-square test. **Fasting blood glucose ≥ 120 mg/
dL. ***Systolic pressure > 130 mmHg. Diastolic pressure > 80 mmHg. NS = 
Nonsigniﬁ  cant.
Table 2: Association of biochemical risk markers among 
the study subjects
Cases 
(N=217)
P* Control (N = 255)
HDL (mg/dL) 49.6 ± 2.4 <0.02 66.2 ± 2.4
LDL (mg/dL) 143 ± 2.4 <0.02 115 ± 3.4 
Serum cholesterol (mg/dL) 188 ± 5.2 <0.04 173.5 ± 3.5 
Serum triglyceride (mg/dL) 157 ± 3.2 <0.02 132.2 ± 2.4
HDL = High density lipoprotein; LDL = Low density lipoprotein.  *P = Calculated 
as Chi-square test.
Table 4: Distribution of MTHFR genotypes in the study 
subjects (overall)
Genotype Cases 
(n, %)
Control 
(n, %)
Crude OR 
(CI%)
P*
CT 47 (21.6) 36 (14.11) 2.17 (88.31–
102.19)
<0.05 
TT 58 (26.72) 33 (12.9) 2.92 (90.52–
103.98)
<0.05
CC 112 (51.6) 186 (72.94) – –
T allele 163 (38.03) 102 (36.12) 3 (228.82–
243.18)
<0.10
C allele 271 (61.96) 408 (63.87) – –
OR = Odd ratio; CI = conﬁ  dence interval; NS = nonsigniﬁ  cant. *P values obtained 
through Chi-square analysis of the differential  genotypes.Dhar, et al.: Genetic predisposition of MTHFR gene polymorphisms
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HDL cholesterol levels were signiﬁ  cantly lower in CAD 
patients than in controls (P < 0.02).
Distribution of different MTHFR genotypes and the allele 
frequencies of the study groups were shown [Tables 3 and 
4], where signiﬁ  cant differences were found between cases 
and controls. The frequencies were almost compatible with 
Hardy–Weinberg equilibrium. We found that the prevalence 
of CC genotype was the highest in subjects. The prevalence 
of C allele was signiﬁ  cantly high in subjects.
Interactions among different polymorphisms of MTHFR 
gene and age, sex, diabetes, hypertension, positive family 
history, different forms of tobacco use and alcohol intake 
were summarized with a view to increase the risk of CADs 
[Table 5]. It was found that smoking (>35 shots/week) and 
tobacco intake (2–3 shots/day), diabetes, hypertension, 
and family history of CAD were signiﬁ  cantly associated 
Table  5:  Association  of  MTHFR genotypes with other risk factors
TT CT CC
Case  
(n,%)
Control 
(n,%)
OR, 
95%CI
P* Case  
(n,%)
Control 
(n,%)
OR, 
95%CI
P* Case Control
Sex
Male 31(14.3) 20(7.8) 0.656 
(0.383- 1.12)
0.123 22(10.13) 17(6.7) 0.425 
(0.238- 0.757)
0.004 59(27.19) 97(38.03)
Female 27(12.4) 13(5.09) 25(11.52) 19(7.4)  53(24.42) 89(34.9)
Age
< 45 years 27(12.44) 14(5.5) 1.381 
(0.789 –2.44)
0.266 22(10.13) 20(7.8) 1.195 
(0.641- 2.22)
0.575 48(22.11) 77(30.2)
>45 years 31(14.28) 19(7.4) 25(11.5) 16(6.3) 64(29.5) 109(42.74)
Smoking
Never 9(4.14) 11(4.3) 12(5.5) 15(5.8) 42(19.35) 74(29.01)
Exsmokers 14(6.5) 6(2.3) 0.26 
(0.117- 0.579)
0.001 8(3.6) 4(1.6) 0.214 
(0.093- 0.4796)
0.002 22(10.13) 48(18.82)
<35 shots/week 16(7.4) 9(3.5) 0.243 
(0.08 – 0.73)
0.012 17(7.8) 9(3.5) 0.25 
(0.084 – 0.762)
0.015 20(9.21) 31(12.15)
>35 shots/week 19(8.7) 7(2.7) 1.42 
(0.144 – 1.28)
0.003 10(4.6) 8(3.13) 1.34 
(1.109 – 1.113)
0.005 28(12.90)    33(12.94)
Other tobacco intake
2-3 shots/day 22(10.18) 13(5.09) 1.2 
(0.124 – 0.447)
0.002 25(11.5) 16(6.27) 1.2 
(0.121-0.455)
0.001 62(28.57) 83(32.5)
Never 36(16.6) 20(7.8) 22(10.1) 20(7.8) 50(23.04) 103(40.39)
Alcohol intake
Heavy 19(8.8) 6(2.4) 0.30 
(0.072 – 1.247)
0.098 11(5.06) 8(3.14) 0.310 
(0.069- 1.395)
0.127 20(9.21) 25(9.8)     
Occasional 17(7.8) 4(1.5) 0.129 
(0.054 – 0.310
0.08 15(6.91) 10(3.9) 0.126 
(0.053 – 0.301)
0.07 28(12.9) 45(17.6) 
Never 22(10.13) 23(9.0) 21(9.7) 18(7.05) 64(29.49)   116(45.49)
Coexistence  of diabetes
Yes 38(17.51) 12(4.7) 1.164 
(1.07 – 1.34)
0.02 19(18.75) 13(5.09) 1.28 
(1.12 – 1.64)
0.003 38(17.59) 67(26.27)
Never 20(9.21) 21(8.23) 28(12.9) 23(9.01)     74(34.10)  119(46.7)
Coexistence of high LDLC
Yes 36(16.6) 13(5.09) 0.254 
(0.130- 0.499)
0.00 26(11.98) 16(6.27) 0.472 
(0.248- 0.899)
0.222 47(21.65) 73(28.62) 
Never 22(10.13) 20(7.84) 21(9.67) 20(7.84) 63(29.03) 113(44.31)
Family history of CAD
Yes 32(14.74) 11(4.31) 1.34 
(1.167- 1.7)
0.004 27(12.44) 17(6.66) 1.2 
(1.117- 1.27)
0.003 27(12.44) 52(20.39)
No 26(11.98) 22(8.62) 20(9.21) 19 (7.45) 85(39.17) 134(52.54)
Coexistence Of hypertension
Yes 48(22.11) 7(2.74) 1.015 
(1.006 – 1.035)
0.005 29(13.36) 7(2.74) 1.02 
(1.008 – 1.049)
0.008 87(40.09) 32(12.54)
Never 10(4.6) 26(10.19) 18(8.29) 29(11.37) 25(11.52) 154(60.39)
OR: Odd Ratio; CI: Conﬁ  dence Interval .* calculated  by  χ²  analysis  comparing  genotype  distributions  among  case  and  control  subjects.Dhar, et al.: Genetic predisposition of MTHFR gene polymorphisms
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between CAD patients and controls in the frequency of 
alleles and genotypes of MTHFR. Coexistence of diabetes 
and hypertension has been reported to be a risk factor 
for the development of CAD.[32] Both hypertension and 
diabetes were more signiﬁ  cantly associated with CT and TT 
genotypes in our study. Family history of CHD has been 
well recognized in some studies.[33,34] However in terms of 
risk factor associated with CAD, we have also observed 
signiﬁ  cantly higher prevalence of CT and TT genotypes 
among the cases who had strong history of development 
of CAD in their ﬁ  rst degree relatives than the controls. 
The LDL, HDL, serum cholesterol, and serum triglyceride 
were found to have statistical correlations with the diseases 
at different signiﬁ  cant levels. Few agreed that high LDL 
cholesterol and low HDL cholesterol are independent risk 
factors for CVD[29,35] and our study also supports it.
In spite of several precautions, our study has certain 
limitations. Our study was hospital-based and could result 
in biased selection in place of random sampling. It has 
been suggested that studies with hospital controls can 
provide lower risk estimates, since diseases of controls 
could be associated with the polymorphisms under study. 
On the other hand, 217 individuals in no way represent a 
population status. Therefore, the study is to be continued 
with more number of study cases. Thus, the associations 
and the underlying mechanisms of lifestyle factors with the 
metabolic enzymes gene polymorphisms still need further 
studies with large-scale (population-based) samples and 
modiﬁ  ed designs.
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